Gary Fishbein
3 Ways to Incorporate Adaptive Trials into Your Oncology Drug Development Plans
June 06 by Andrea CharlesThe lengthy clinical development process of drug development for life threatening diseases is not an optimal development strategy for oncology therapeutic area. Adaptive designs have become popular to...
The Failure Rate at Phase Three is Probably 70% or Greater
April 23 by Surya Chitra, PhD, MBA, Biostatistics and Pharmacology, and Gary Fishbein, MD, MPH,Surya Chitra, PhD, MBA, Biostatistics and Pharmacology, and Gary Fishbein, MD, MPH, Senior Medical Director, PharmaNet Development Group, Inc, join Pharma IQ to discuss adaptive trial design. Pharma...